| Similar Articles |
|---|
 |
The Motley Fool
October 2, 2009
Brian Orelli |
A Plasma-tastic IPO Talecris Biotherapeutics debuted on the public markets yesterday, raising $950 million for the company. That's the second largest IPO of the year so far.   |
The Motley Fool
February 3, 2009
Robert Steyer |
An Emerging Medical Power Take a look at a company whose stock price has quintupled over the past five years: Australia-based pharmaceutical CSL. And this could be just the beginning of great things to come. |
The Motley Fool
September 2, 2010
Seth Jayson |
Checking for Revenue Tricks at Talecris Biotherapeutics Holdings Is Talecris sending any warning signs about its health? Take a look at the chart below, which plots revenue growth against accounts receivable growth and days sales outstanding. |
The Motley Fool
December 9, 2010
Seth Jayson |
Don't Get Too Worked Up Over Talecris Biotherapeutics' Earnings With 13.9% of operating cash flow coming from questionable sources, Talecris Biotherapeutics investors should take a closer look at the underlying numbers. |
